peoplePerson
Jennifer K. Litton
Jennifer Litton led the EMBRACA trial that brought talazoparib to BRCA-mutated breast cancer.
Breast medical oncologist who was principal investigator of EMBRACA and of neoadjuvant talazoparib studies in germline BRCA carriers. Oversees clinical research operations across MD Anderson.
Role
Vice President, Clinical Research; Professor of Breast Medical Oncology, MD Anderson
Institution
Specialisms
Breast cancerBRCAPARP inhibitors
| Title | Journal | Year |
|---|---|---|
| Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation | New England Journal of Medicine | 2018 |
| Neoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline BRCA Pathogenic Variant | Journal of Clinical Oncology | 2020 |